These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 19347233)

  • 1. Potential of small molecule protein tyrosine kinase inhibitors as immuno-modulators and inhibitors of the development of type 1 diabetes.
    Little PJ; Cohen N; Morahan G
    ScientificWorldJournal; 2009 Mar; 9():224-8. PubMed ID: 19347233
    [No Abstract]   [Full Text] [Related]  

  • 2. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice.
    Louvet C; Szot GL; Lang J; Lee MR; Martinier N; Bollag G; Zhu S; Weiss A; Bluestone JA
    Proc Natl Acad Sci U S A; 2008 Dec; 105(48):18895-900. PubMed ID: 19015530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there a role for imatinib mesylate in the treatment of eosinophilic granulomatosis with polyangiitis?
    Erre GL; Pardini S; Cuccuru L; Taras L; Passiu G
    Joint Bone Spine; 2015 Jan; 82(1):72-3. PubMed ID: 25059880
    [No Abstract]   [Full Text] [Related]  

  • 4. 3. Imatinib therapy in chronic myelogenous leukemia.
    Jinnai I
    Intern Med; 2007; 46(2):95-7. PubMed ID: 17220607
    [No Abstract]   [Full Text] [Related]  

  • 5. Mutational analysis and overcoming imatinib resistance in chronic myeloid leukemia with novel tyrosine kinase inhibitors.
    Mauro MJ
    Curr Treat Options Oncol; 2007 Aug; 8(4):287-95. PubMed ID: 18157514
    [No Abstract]   [Full Text] [Related]  

  • 6. Moving targets in hepatocellular carcinoma: hepatic progenitor cells as novel targets for tyrosine kinase inhibitors.
    Siegel A
    Gastroenterology; 2008 Sep; 135(3):733-5. PubMed ID: 18692053
    [No Abstract]   [Full Text] [Related]  

  • 7. Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes.
    Mokhtari D; Welsh N
    Clin Sci (Lond); 2009 Nov; 118(4):241-7. PubMed ID: 19886867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib and regression of type 2 diabetes.
    Veneri D; Franchini M; Bonora E
    N Engl J Med; 2005 Mar; 352(10):1049-50. PubMed ID: 15758023
    [No Abstract]   [Full Text] [Related]  

  • 9. Mechanisms of clinical resistance to small molecule tyrosine kinase inhibitors targeting oncogenic tyrosine kinases.
    van der Kuip H; Wohlbold L; Oetzel C; Schwab M; Aulitzky WE
    Am J Pharmacogenomics; 2005; 5(2):101-12. PubMed ID: 15813673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hits and misses in targeting pediatric cancers.
    Bernstein ML
    Pediatr Blood Cancer; 2009 Jul; 52(7):751-2. PubMed ID: 19185009
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
    Agostino NM; Chinchilli VM; Lynch CJ; Koszyk-Szewczyk A; Gingrich R; Sivik J; Drabick JJ
    J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Resistance against tyrosine kinase inhibitors in the treatment of GIST. New therapeutic possibilities appear].
    Ahlman H; Nilsson O; Nilsson B
    Lakartidningen; 2009 Dec 9-21; 106(50-51):3424-9. PubMed ID: 20180446
    [No Abstract]   [Full Text] [Related]  

  • 13. [Tyrosine kinase inhibitors].
    Yagasaki F
    Nihon Naika Gakkai Zasshi; 2007 Jul; 96(7):1411-9. PubMed ID: 17682429
    [No Abstract]   [Full Text] [Related]  

  • 14. Limited efficacy of imatinib in severe pulmonary chronic graft-versus-host disease.
    Stadler M; Ahlborn R; Kamal H; Diedrich H; Buchholz S; Eder M; Ganser A
    Blood; 2009 Oct; 114(17):3718-9; author reply 3719-20. PubMed ID: 19850751
    [No Abstract]   [Full Text] [Related]  

  • 15. [Consensus on the medical treatment of gastrointestinal stromal tumors].
    Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):875-7. PubMed ID: 18396652
    [No Abstract]   [Full Text] [Related]  

  • 16. [Updates on pathology of soft tissue tumors].
    Yu L; Wang J
    Zhonghua Bing Li Xue Za Zhi; 2013 Mar; 42(3):145-6. PubMed ID: 23769430
    [No Abstract]   [Full Text] [Related]  

  • 17. Is there a role for imatinib in inflammatory bowel disease?
    De Backer O; Lefebvre RA
    Inflamm Bowel Dis; 2008 Apr; 14(4):579-81. PubMed ID: 18050299
    [No Abstract]   [Full Text] [Related]  

  • 18. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.
    Wu J; Meng F; Kong LY; Peng Z; Ying Y; Bornmann WG; Darnay BG; Lamothe B; Sun H; Talpaz M; Donato NJ
    J Natl Cancer Inst; 2008 Jul; 100(13):926-39. PubMed ID: 18577747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel approaches to therapy of hypereosinophilic syndromes.
    Simon HU; Cools J
    Immunol Allergy Clin North Am; 2007 Aug; 27(3):519-27. PubMed ID: 17868862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards a cure for chronic myeloid leukemia: are we there yet?
    Cortes J
    Semin Hematol; 2010 Oct; 47(4):299-301. PubMed ID: 20875545
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.